When Cancer Vaccines Go Viral.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31227502.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1652.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Induction of antitumor responses by vaccines requires strong immunogens. Heterologous viral prime/boost immunization with the BN-CV301 vaccine promotes activation of immune responses that provide a clinical benefit to patients with cancer. This viral platform may be used to harbor different antigens and prime tumor immunity potentially useful for combinatorial strategies.<i>See related article by Gatti-Mays et al., p. 4933</i>.
Medical subject headings
- Cancer Vaccines
- Vaccines, DNA